Open AccessCirculating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals
Author(s) -
Daniel D. Murray,
Kazuo Suzuki,
Matthew Law,
Jonel Trebicka,
Jacquie Neuhaus Nordwall,
Margaret Johnson,
Michael J. Vjecha,
Anthony D. Kelleher,
Sean Emery
Publication year - 2017
Publication title -
scientific reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.24
H-Index - 213
ISSN - 2045-2322
DOI - 10.1038/s41598-017-11405-8
Subject(s) - disease , liver disease , mir 122 , population , microrna , human immunodeficiency virus (hiv) , immunology , extracellular vesicles , liver damage , medicine , biology , virology , pathology , virus , hepatitis c virus , gene , environmental health , genetics , microbiology and biotechnology
Liver disease is one of the main contributors to the increased levels of morbidity and mortality seen in the HIV-1-infected, ART-treated population. Circulating miRNAs, particularly those located inside extracellular vesicles, are seen as promising biomarkers for a number of human disease conditions, including liver-related diseases. Here, we show that serum levels of miR-122 and miR-200a are greater in HIV/HCV co-infected individuals compared to HIV-1 mono-infected individuals. We also show that miR-122 and miR-200a are elevated in ART-treated, HIV-1-infected individuals prior to the development of fatal liver disease, suggesting that these miRNA may have some potential clinical utility as biomarkers. While this study is hypothesis generating, it shows clearly that both miR-122 and miR-200a are promising novel biomarkers for liver disease in the ART-treated, HIV-1-infected population.